ATE259365T1 - Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase - Google Patents

Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase

Info

Publication number
ATE259365T1
ATE259365T1 AT00309627T AT00309627T ATE259365T1 AT E259365 T1 ATE259365 T1 AT E259365T1 AT 00309627 T AT00309627 T AT 00309627T AT 00309627 T AT00309627 T AT 00309627T AT E259365 T1 ATE259365 T1 AT E259365T1
Authority
AT
Austria
Prior art keywords
protein transferase
compounds
quinoline derivatives
inhibiting farnesyl
derivatives usable
Prior art date
Application number
AT00309627T
Other languages
English (en)
Inventor
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE259365T1 publication Critical patent/ATE259365T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00309627T 1999-11-30 2000-11-01 Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase ATE259365T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16820799P 1999-11-30 1999-11-30
US17011999P 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
ATE259365T1 true ATE259365T1 (de) 2004-02-15

Family

ID=26863889

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00309627T ATE259365T1 (de) 1999-11-30 2000-11-01 Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase

Country Status (12)

Country Link
US (1) US6596735B1 (de)
EP (1) EP1106612B1 (de)
JP (1) JP2001213876A (de)
AT (1) ATE259365T1 (de)
BR (1) BR0005633A (de)
CA (1) CA2327026A1 (de)
DE (1) DE60008206T2 (de)
DK (1) DK1106612T3 (de)
ES (1) ES2212971T3 (de)
MX (1) MXPA00011856A (de)
PT (1) PT1106612E (de)
TR (1) TR200400342T4 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
DE60118225T2 (de) 2000-09-25 2007-05-03 Janssen Pharmaceutica N.V. Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US7067148B2 (en) 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
WO2004056806A1 (en) 2002-12-19 2004-07-08 Pfizer Inc. 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Gtpアーゼ阻害剤および使用方法
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
CA2561516A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
ME01309B (me) * 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
BRPI0514687A (pt) * 2004-08-26 2008-06-17 Pfizer compostos amino heteroarila como inibidores de proteìna tirosina cinase
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
WO2007016539A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
CA2621371C (en) 2005-09-07 2018-05-15 Amgen Fremont Inc. Human monoclonal antibodies to activin receptor-like kinase-1
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
DK2056874T3 (da) 2006-08-21 2012-10-15 Hoffmann La Roche Tumorterapi med et anti-vegf-antistof
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
WO2011093365A1 (ja) * 2010-01-27 2011-08-04 協和発酵キリン株式会社 含窒素複素環化合物
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (de) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ES2619610T3 (es) 2012-10-16 2017-06-26 Janssen Pharmaceutica Nv Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo
MY189505A (en) 2012-10-16 2022-02-16 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of roryt
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
ES2742843T3 (es) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv Moduladores de quinolinilo de ROR(gamma)t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
CN108601752A (zh) 2015-12-03 2018-09-28 安吉奥斯医药品有限公司 用于治疗mtap缺失型癌症的mat2a抑制剂
CA3151110A1 (en) 2019-08-16 2021-02-25 Children's Hospital Medical Center Methods of treating a subject with a cdc42-specific inhibitor
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2024137751A1 (en) * 2022-12-21 2024-06-27 Kura Oncology, Inc. Methods of treating advanced solid tumors
WO2024233539A1 (en) * 2023-05-09 2024-11-14 Kura Oncology, Inc. Methods of treating squamous cell carcinoma with a farnesyltransferase inhibitor and a pi3k inhibitor
TW202519226A (zh) * 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制pkmyt1之化合物治療癌症之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) * 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CN100525766C (zh) * 1997-06-02 2009-08-12 詹森药业有限公司 用作平滑肌细胞增殖抑制剂的(咪唑-5-基)甲基-2-喹啉酮衍生物
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
SK11002001A3 (sk) * 1999-02-11 2002-05-09 Pfizer Products Inc. Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky

Also Published As

Publication number Publication date
CA2327026A1 (en) 2001-05-30
EP1106612B1 (de) 2004-02-11
TR200400342T4 (tr) 2004-03-22
DE60008206T2 (de) 2004-12-02
DE60008206D1 (de) 2004-03-18
PT1106612E (pt) 2004-06-30
DK1106612T3 (da) 2004-05-17
EP1106612A1 (de) 2001-06-13
BR0005633A (pt) 2001-07-17
US6596735B1 (en) 2003-07-22
ES2212971T3 (es) 2004-08-16
JP2001213876A (ja) 2001-08-07
MXPA00011856A (es) 2002-06-04

Similar Documents

Publication Publication Date Title
ATE259365T1 (de) Chinolinderivate verwendbar zur hemmung der farnesyl-protein transferase
ATE242231T1 (de) Carbonyl-piperaznyl und piperidinyl derivate zur hemmung farnesyl protein transferase
BG66087B1 (bg) Хинолинонови производни като тирозин киназни инхибитори
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
EP1156045A4 (de) Amid-derivate und drogen-zusammensetzungen
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
HUP0101146A2 (hu) Foszfolipáz enzim inhibitor hatású indolszármazékok, valamint a vegyületeket tartalmazó gyógyászati készítmények
NO944643L (no) Protein-kinase-C-hemmere
UY25679A1 (es) Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
ATE321038T1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
PT928788E (pt) Compostos farmaceuticamente activos
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
TW200420545A (en) 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives
PT992509E (pt) Novos derivados macrolidos
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
BG106044A (en) Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
IL149306A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
ATE409698T1 (de) 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung
BR9908948A (pt) Composição farmacêutica contendo um inibidor de protease cisteìna para profilaxia e terapia de dano ao tecido cerebral

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1106612

Country of ref document: EP

REN Ceased due to non-payment of the annual fee